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1. Introduction
Gestational diabetes mellitus (GDM) is a glucose intolerance of varying severity with onset or
first recognition, during pregnancy that complicates 2–4% of pregnancies (Ben-Haroush et al
2004, American Diabetes Association 2005, NICE Guidelines 2008). Both patients with GDM,
and their offspring, have greater risk of developing type 2 diabetes later in life (Damn 1998).
There is a close relationship between GDM and prediabetes state in addition to the risk of
future deterioration in insulin resistance and ultimate development of overt type 2 diabetes
mellitus (Kjos et al 1999). Diabetes in pregnancy is increasing and therefore it is important to
raise awareness of the associated health risks to the mother, the growing fetus, and the future
child. Perinatal mortality and morbidity is increased in diabetic pregnancies through increased
stillbirths and congenital malformation rates (Canadian Diabetes association 2003, HAPO
2008, RCOG SAC 2011). These are mainly the result of early fetal exposure to maternal
hyperglycaemia. In the mother, pregnancy may lead to worsening or development of diabetic
complications such as retinopathy, nephropathy, and hypoglycaemia (Ali and Dornhorst
2011). Although glycaemic control is important in reducing microvascular complications due
to diabetes in pregnancy, it has not reduced the rate of congenital anomalies, macrosomia and
other adverse outcomes (Canadian Diabetes Association 2003). This may be as a result of our
lack of understanding of the epidemiology and pathogenesis of GDM (Omu et al. 2010),
especially the role of inflammation, cytokines and lipid metabolism.
1.1. The main objectives of this review are to draw attention to
a. The epidemiology, genetics and immunological basis of GDM
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Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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b. Elucidate the effect of lipid metabolism and lipid peroxidation, oxidative stress on
antioxidant gene expression and other inflammatory cytokines.
c. Investigate the role of risk factors including obesity and adipokines like adiponectin,
leptin and tumor necrosis factor alpha, acute phase proteins like C-reactive protein (C-
RP), IL-6 and plasminogen activation inhibitor -1 (PAI-1) and proinflammatory Cytokines
and the mechanisms involved in the pathogenesis.
d. Highlight the role of intervention strategy in the prevention of progression of GDM to
type 2 Diabetes Mellitus and alteration of Maternal effects of GDM
2. Epidemiology of gestational diabetes mellitus
Gestational diabetes has been recognised as a heterogenous disorder of glucose intolerance
(Kjos et al 1999, Metzger et al 2010, and Omu et al 2011). Unfortunately, comparisons of
frequencies of GDM among various populations is difficult because, there are differences in
screening programmes and diagnostic criteria (Butte 2000, Ben-Haroush et al 2004, Buchanan
et al 2007). There is an urgent need to develop and unify appropriate diabetic diagnostic and
prevention strategies and address potentially modifiable risk factors such as obesity.
2.1. Diagnostic criteria of gestational diabetes mellitus (GDM)
Historically, the diagnosis of gestational diabetes mellitus (GDM), like diabetes mellitus in
general, has been by measuring the fasting plasma glucose level and performing an oral
glucose tolerance test (OGGT) with the threshold as shown in Table 1. In 2010, the American
Diabetic Association added haemoglobin A1c (Hb A1c) as a diagnostic tool for individual with
type 2 diabetes mellitus with a threshold fixed at 6.5 % for diagnosis. It was however, not
recommended for use in GDM.
mg/dl mmol/L
100g glucose load
Fasting 95 5.3
1 hour 180 10.0
2 hour 155 8.6
3 hour 140 7.8
75 g glucose load
Fasting 95 5.3
1 hour 180 10.0
2 hour 155 8.6
Table 1. Diagnosis of Gestational Diabetes Mellitus (GDM)
For diagnosis of GDM, 2 values in each diagnostic group must be met or exceeded (ADA 2011).
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According to the NICE guidelines No 63 (2008), screening for GDM using fasting plasma
glucose, random blood glucose, glucose challenge test and urinalysis for glucose, should not
be recommended. Instead a 2 hour 75 g OGTT should be done at 24-28 weeks of gestation.
2.2. Non-genetic factors
Ethnicity, old age, family history, obesity and high fat diet and sedentary lifestyle, represent
some important non-genetic identifiable predisposing factors for GDM, and in the absence
of  risk  factors,  there  is  low  incidence  of  GDM.  Ethnicity  has  been  proven  to  be  an
independent risk factor for GDM (Dooley et al 1991, Weerakiet et al.  2004) which varies
in prevalence in direct proportion to the prevalence of Type 2 diabetes in a given popula‐
tion or ethnic group. Women with an early diagnosis of GDM, in the first half of pregnan‐
cy, represent a high-risk subgroup, with an increased incidence of obstetric complications,
recurrent GDM in subsequent pregnancies, and future development of Type 2 diabetes(Ben-
Housah et al 2004, Buchanan et al 2007). There is a strong association between Gestation‐
al  Diabetes  Mellitus  and  women  with  diagnosed  Polycystic  Ovary  Syndrome  (PCOS)
(Weerakiet  et  al  2004,  Lo  et  al  2006).  The  prevalence  of  GDM is  increasing  worldwide
because of the obesity epidemic and the increasing sedentary lifestyle and the attractive
high caloric intake and need for insulin for glycaemic control (Bray et al 2003, Hedley et
al 2004, Callagher et al 2008, Kulie et al. 2011, WHO 2011).
2.3. Postpartum diabetes mellitus
Gestational Diabetes Mellitus increases the risk of developing Type1 and Type 2 diabetes
mellitus. Risk estimates for type 2 Diabetes is 17 to 68 percent within 5-16 years after pregnancy
(O’Sullivan 1991, Hanna et al. 2002, Ben-Housah et. al 2004). The risk factors for postpartum
diabetes include islet autoantibody positivity, insulin requirement during pregnancy, Obesity
(Lauenborg et al 2004) and strong family history.
2.4. Genetics of GDM
GDM is considered to result from interaction between genetic and environmental risk factors.
Women with mutations in MODY (Maturity onset diabetes of the young) genes often present
with GDM. Genetic predisposition to GDM has been suggested given the occurrence of the
disease within family members. GDM is reported to be often present in women with mutation
of MODY gene mutations (Lapolla et al 1996, Ferber et al. 1999, Watanabe et al 2007). Candidate
susceptibility gene variants have been suggested to increase the risk of GDM. These genes
include glucokinase (GCK), HLA antigens, insulin receptor (INSR), insulin-like growth
factor-2 (IGF2), insulin gene (INS-VNTR), plasminogen activator inhibitor 1 (PAI-1), potassium
inwardly rectifying channel subfamily J, member 11 (KCNJ11), hepatocyte nuclear factor-4a
(HNF4A) (Love-Gregory and Permutt 2007). Identification of the possible underlying genetic
factors and mechanisms of the pathogenesis may contribute to the individualization of both
prevention and treatment of complications for the mother and fetus (Lambrinoudaki et al
2010). Furthermore, it may improve options to prevent GDM and the complications for the
mother and child (Shaat and Groop 2007). During pregnancy, pancreatic cells should by
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necessity, expand and produce more insulin to adapt to the needs of the pregnancy and the
growing baby. Hepatic Growth Factor (HGF) which interact with a surface receptor called c-
Met. HGF/c-Met pathway signaling, plays a key role in increasing insulin secretion during
pregnancy. The mechanisms in the maternal β-cells adaptation during pregnancy include
maternal β-cell hyperplasia by lactogens and HGF/c-Met (Ernst et al 2011). Loss of HGF/c-Met
Signaling in Pancreatic β-Cells leads to incomplete Maternal β-Cell Adaptation and Gesta‐
tional Diabetes Mellitus (Demirci et al 2012).
3. Lipid metabolism and gestational diabetes mellitus
3.1. Lipid and lipoproteins
Hyperlipidemia is a common comorbidity among patients with diabetes mellitus (Anger et al
2011, Koukkou et al 2011). A recent study has found an association between cholesterol intake
and GDM (Gonzalez-Clemente et al. 2007 ). In the placenta, expressions of key proteins
involved in de novo lipid synthesis are affected by changes in maternal metabolism (hyper‐
cholesterolemia and GDM) that may subsequently affect fetal development and result in
asymmetric macrosomia. In addition, impaired placental function gives rise to significant
increases in LDL, Apo-B-100 and triglyceride in maternal serum with increased levels of fatty
acid synthase (FAS) and SREBP-2 expression and inflammatory cytokines (IL-1β and TNF-α)
in placenta (Marseille-Trembley et al 2008). This may give rise to trend towards an increased
risk of cardiovascular disease (Gonzalez-Clemente et al. 2007).
3.2. Free fatty acids
Free fatty acids (FFA) are the main circulating lipid fuel. FFA released from visceral depot
appear to serve as a marker of systemic insulin resistance and associated increases in cardio‐
vascular risk (Sivan et al 1999, Catalano et al 2002, Jensen 2006). This has been attributed to
apoptosis of pancreatic beta cells through pathway involving caspase and ceramide as a
mechanism underlying FFA induced impairment of beta –cell function (Turpin et al 2006).
Hyperglycaemia and elevated FFA may act synergistically in causing damage to beta cells (El-
Assaad et al 2003) and decreases ability of insulin to suppress free fatty acids with advancing
gestation with GDM (Darmady and Postle 1982). In a recent report, Schaefer and Colleagues
(2011) demonstrated higher free fatty acids in the cord blood of those neonates from mothers
with gestational diabetes, indicating their enhanced placental transport and/or enhanced
lipolysis as a result of decreased insulin responsiveness (Kautzky-Willer et al 2003).
3.3. Effects of lipid peroxidation
The markers of lipid oxidation, especially malondialdehyde (MDA) increased with hypergly‐
caemia (Davi et al. 2005). Lipid peroxidation is a crucial process generated naturally in the
body, mainly by the effect of several reactive oxygen species such as hydroxyl radical,
hydrogen peroxide and superoxide. These reactive oxygen species readily attack the polyun‐
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saturated fatty acids of the fatty acid membrane, initiating a self-propagating chain reaction
(Hanachi et al. 2009). The destruction of membrane lipids and the end-products of such lipid
peroxidation reactions cause cell damage. Enzymatic (catalase, superoxide dismutase) and
nonenzymatic (vitamins A and E) natural antioxidant defense mechanisms exist; however,
these mechanisms may be overcome, causing lipid peroxidation to take place. Lipid peroxi‐
dation has been implicated in disease states such as atherosclerosis, asthma, Parkinson's
disease, kidney damage and preeclampsia (Mylonas and Kouretas 1999, Veskoukis et al 2012)
3.4. Effect of lipid metabolism on neonatal outcome
The development of diabetes in pregnancy induces a state of dyslipidemia, characterized by
a high triglyceride concentration (Koukkon et al 1996,) and associated with disturbance of fetal
development with modification of key features of placental function (Marseille-Tremblay
2008). GDM patients with macrosomic fetuses are associated with higher lipid and lipoprotein
concentrations than in control patients (Mersouk et al. 2000).
8-Isoprostane is a product of lipid peroxidation that can be used as a measure of free radical
exposure or injury. Periventricular-intraventricular hemorrhage, necrotizing enterocolitis,
chronic lung disease and retinopathy of prematurity have been referred to as oxygen radical
diseases (ORD) because they are thought to be related to excess oxidant stress relative to anti-
oxidant defenses in premature infants (Weinberger et al 2006). Umbilical cord venous, but not
arterial, 8-isoprostane levels are associated with mortality and the development of one or more
of the ORD. In a study, serum triglyceride, total cholesterol, and LDL-c concentrations were
higher in the SGA neonates than in AGA neonates, whereas high-density lipoprotein choles‐
terol concentrations were similar, suggesting a limited ability to clear intravenous lipids in
SGA infants (Arends et al 2005). These findings are in agreement with many previous studies
in adults and children that show that low birth weight was significantly associated with a less
favorable lipid profile (Mortaz et al 2001). Hyperinsulinemia is known to enhance hepatic very-
low-density lipoprotein synthesis, which may contribute to increased plasma triglycerides and
LDL-c levels. Resistance to the action of insulin on lipoprotein lipase in peripheral tissues may
also contribute to elevated triglyceride and LDL-c levels. (Barker et al 1993).
3.5. Adipose tissue as an endocrine organ
The discovery of leptin in the mid-1990s has focused attention on the role of proteins secreted
by adipose tissue (Wang et al 2004). Leptin has profound effects on appetite and energy
balance, and is also involved in the regulation of neuroendocrine and immune function. Sex
steroid and glucocorticoid metabolism in adipose tissue have been implicated as a determinant
of body fat distribution and cardiovascular risk. Other adipose products, include other
adipokines such as adiponectin, proinflammatory cytokines such as TNF-alpha and IL-6, C-
Reactive Protein, complement factors (Cipollini et al 1999, Coppack 2001) and components of
the coagulation/fibrinolytic cascade like plasminogen activation inhibitor-1 (PAI-1), that may
mediate the metabolic and cardiovascular complications associated with obesity and insulin
resistance (Ahima and Flier 2000, Hutley and Prins 2005, Jensen 2006).).
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4. Immunology of gestational diabetes
Pregnancy represents a distinct immunologic state in the fetus that acts as an allograft to the
mother, needing protection against potential rejection. There is some evidence that inflamma‐
tion and activated innate immunity is associated with the pathogenesis of Type 2 Diabetes
(Pickup 2004), but this needs comfirmation, especially in GDM.
4.1. Humoral reactivity in pregnancy
The placental HLA-G proteins facilitate semiallogeneic pregnancy by inhibiting maternal
immune responses to foreign (paternal) antigens via their actions on immune cells is now well
established, and the postulate that the recombinant counterparts of these proteins may be used
as powerful tools for accommodating the fetus and prevent immune rejection (Hunt et. al
2005). Humoral immune-reactivity does not change much during pregnancy, with the
exception of lowered immunoglobulin G concentration at late phase, probably explained by
placental transport. Regarding cellular immunity, the reduction, elevation, and lack of
variation in the number of different lymphocytic populations, have been reported (Mahmoud
et al 2005, 2006).
4.2. Autoimmune GDM
Multiple autoimmune disturbances may be manifested during pregnancy (Leiva et al 2008).
Ferber and Associates (1999) have demonstrated that women with GDM who have islet
autoantibodies at delivery or develop IDDM postpartum have HLA alleles typical of late-onset
type 1 diabetes, and that both HLA typing and islet antibodies can therefore predict the
development of postpartum IDDM. Freinkel et al. (1986) first proposed what may be defined
as autoimmune GDM; that GDM entails genotypic and phenotypic diversity which may
include patients with slowly evolving type 1 diabetes (Mauricio and Leiva 2001, Lapolla et al
2009). There is current consensus that autoimmune GDM is a heterogeneous condition that
accounts for 10% of all Caucasian women diagnosed with GDM (Mauricio et al 1996). As a
high-risk group for type 1 diabetes, women with previous autoimmune GDM may be candi‐
dates for potential immune intervention strategies (Mauricio et al 2001).
4.3. Cellular immune response and gestational diabetes
There is a significant increase in the absolute number of total and activated (CD3+HLA-DR+)
T lymphocytes and a significant increase in the absolute number and percentage of suppressor/
cytotoxic T lymphocytes (CD8) and NK lymphocytes (CD57) in GDM patients compared with
normal pregnant controls (Mahmoud et al.2006). Concerning frequency for HLA A, B, C, DR
antigens in the GDM population, only Cw7 was found to be significantly increased and A10
significantly decreased in comparison with controls (Lapolla et al 1996). When compared with
healthy pregnant women, both GDM cohorts showed higher percentages CD4+CD25+ (P <
0.05), CD4+CD45RO+ (P < 0.05) and CD4+CD29+ (Mahmoud et al 2005).
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5. The placenta is a target of cytokines: maternal and fetal influences
There is a robust cytokine network in the placenta with diverse pathogenesis and effects on
the development of the fetus.
5.1. Bidirectional nature of cytokine at the fetal-maternal interface
Subpopulations of T helper lymphocytes (CD3+/CD4+) can be classified as either T helper 1
(Th1) or T helper 2 (Th2) cells depending on their cytokine profiles. Th2 cells selectively
produce interleukins (IL)‐4, IL‐5, IL‐6, IL‐9, IL‐10 and IL‐13, and are involved in the develop‐
ment of humoral immunity against extracellular pathogens but inhibit several functions of
phagocytic cells. In contrast to this, Th1 cells produce interferon‐γ (IFN‐γ), IL‐2 and tumour
necrosis factor‐α (TNF‐α) and evoke cell‐mediated immunity and phagocyte‐dependent
inflammation (Mosmann et al 1989, Mosmann and Moore 1991, Romagnani 2000). Cytokines
are mainly produced by cells of the immune system, NK cells, and macrophages in response
to an external stimulus such as stress, injury, and infection. Adipose tissue represents an
additional source of cytokines, making possible a functional cooperation between the immune
system and metabolism (Guerre-Miller 2004, Radaelli et al. 2005).
5.2. The role of adipokines and other inflammatory markers
Research  has  recently  focused  on  a  group  of  substances  produced  mainly  by  adipose
tissue called adipokines,  this  group includes,  among others,  adiponectin,  leptin,  Retinol-
Binding Protein-4  (RBP-4),  and resistin.  These substances  as  well  as  other  inflammatory
mediators  (CRP,  IL-6,  PAI-1,  TNF-α)  seem  to  play  an  important  role  in  glucose  toler‐
ance  and  insulin  sensitivity  dysregulation  in  women  with  GDM  (Thyfault  et  al  2005,
Defalu  2009).  There  are  two  main  pathways  leading  to  GDM  and  T2DM:  insulin
resistance  and  chronic  subclinical  inflammation.  Insulin  resistance  is  caused  by  the
inability  of  tissues  to  respond  to  insulin  and  the  deficient  secretion  of  insulin  by
pancreatic  beta  cells  (Vrachnis  et  al  2012).  Inflammatory  processes  have  a  robust
contribution to  the pathogenesis  of  dysglycemia condition and acute  phase inflammato‐
ry  response  is  a  risk  factor  for  T2DM and cardiovascular  disease  [Pickup et  al.  2004  ].
Obesity  has  a  role  in  the  development  of  both  T2DM  and  GDM  through  chronic
subclinical  inflammation,  low-grade activation of  the acute phase response,  and dysregu‐
lation  of  adipokines  (Yudkin  et  al  1999,  Greenberg  et  al  2002).  Increased  levels  of
inflammatory  agents  during  and  after  pregnancy  have  been  reported  in  patients  with
GDM,  while  increased  body  fat  has  been  strongly  associated  with  inflammation  and
adipocyte  necrosis,  hypoxia,  and  release  of  chemokines  which  cause  macrophages  to
infiltrate  adipose  tissue.  Macrophages  secrete  cytokines  which  activate  the  subsequent
secretion  of  inflammation  mediating  agents,  specifically  interleukin-6  (IL-6)  and  C-
reactive  protein  (CRP)  (Festa  et  al  2000).  Other  molecules  such  as  Plasminogen Activa‐
tor  Inhibitor  1  (PAI-1)  and  sialic  acid  lead  to  dysregulations  of  metabolism,
hyperglycemia,  insulin resistance,  and diabetes.  These are a  group of  substances that  are
produced  mainly  in  the  adipose  tissue.  The  group  includes  leptin,  adiponectin,  tumor
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necrosis  factor  alpha  (TNF-α),  retinol-binding  protein-4  (RBP-4),  resistin,  visfatin,  and
apelin.  These  molecules  are  involved  in  a  wide  range  of  physiological  processes
including  lipid  metabolism,  atherosclerosis,  blood  pressure  regulation,  insulin  sensitivi‐
ty,  and angiogenesis,  while  they also influence immunity and inflammation.  Their  levels
in  pathologic  states  appear  increased,  with  the  exception  of  adiponectin  which  shows
decreased levels  (Vrachnis  et  al  2012).
5.3. Adiponectin
Since the discovery of adiponectin in 1994 by Jeffrey M. Friedman (Zhang et al 1994), more
than 20 members of the adiponectin family have been identified (Klein et al 2002, Housa
et  al  2006).  Adiponectin  is  a  30-kDa  protein  that  is  synthesized  almost  exclusively  by
adipocytes.  It  exists  in  three  major  oligomeric  forms:  a  low-molecular-weight  trimer,  a
middle-molecular-weight  hexamer  and  high-molecular-weight  (HMW)  12-  to  18-mer
adiponectin.  It  is  an insulin-sensitizing and stimulates glucose uptake in skeletal  muscle
and reduces hepatic glucose production through AMP-activated protein kinase[Zavalza et
al 2008]. Circulating adiponectin levels are reduced in patients with GDM as compared to
healthy pregnant controls. Adiponectin mRNA is downregulated in placental tissue, while
circulating adiponectin concentrations are decreased postpartum in women with a history
of GDM. It also possesses antiatherogenic and anti-inflammatory properties [Chandran et
al  2003,  Wiecek  et  al  2007].  The  levels  of  adiponectin  decrease  as  visceral  fat  increases
[Cnop etal 2003, Weyer et al 2001, Hotta et al 2000, Shondorf et.  al 2005] in such condi‐
tions  as  central  obesity,  insulin  resistance,  and  diabetes  mellitus.  Reduced  adiponectin
levels have notably been associated with subclinical inflammation [Retnakaran et al 2003].
It has been shown that adiponectin levels begin to decrease early in the pathogenesis of
diabetes, as adipose tissue increases in tandem with reduction in insulin sensitivity [Hotta
et  al  2001].  Hypoadiponectinemia  has  also  been  associated  with  beta  cell  dysfunction
[Musso et al 2005, Retnakaran et al 2005)], while it has additionally been linked to future
development  of  insulin  resistance  and  type  2  diabetes  mellitus,  in  the  development  of
which adiponectin appears to have a causative role (Stefan et al 2002). As such, adiponec‐
tin may play a key role in mediating insulin resistance and beta cell  dysfunction in the
pathogenesis of  diabetes (Retnakaran et  al  2004,  Retnakaran et  al  2005).  Retnakaran and
Associates  (2005)  have  demonstrated  that  adiponectin  concentration  is  an  independent
correlate of pancreatic beta cell function in late pregnancy.
5.4. Leptin
Leptin is a 16-kDa protein hormone that is known to play a key role in the regulation of
energy  intake  and  energy  expenditure  and  in  a  number  of  physiological  processes
including  regulation  of  endocrine  function,  inflammation,  immune  response,  reproduc‐
tion and angiogenesis. The main function of leptin in the human body is the regulation of
energy expenditure and control  of  appetite.  Indeed,  lack of  leptin in mice with a muta‐
tion in the gene encoding leptin, or absence of functional leptin receptor (db/db mice) results
in obesity and many associated metabolic complications such as insulin resistance [Ceddia
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et al 2002)]. Leptin is a key molecule in obesity and it is predominantly produced by white
adipose  tissue  [Harvey  and  Ashford  2003].  Circulating  leptin  is  actively  transported
through the blood-brain barrier  and acts  on the hypothalamic satiety center  to decrease
food intake. Serum level of leptin reflects the amount of energy stored in the adipose tissue
and proportional to body fat mass [Fruhbeck 2006], i.e. increased in obese and decreased
after  several  months of  pronounced weight loss [Moschen et  al  2009,  Hegyi  et  al  2004].
Thus,  it  increases  insulin  sensitivity  by influencing insulin  secretion,  glucose utilization,
glycogen  synthesis  and  fatty  acid  metabolism,  regulates  gonadotrophin  releasing  hor‐
mone  secretion  from  the  hypothalamus  and  activates  the  sympathetic  nervous  system.
Leptin  acts  via  transmembrane  receptors  (OB-R),  which  belong  to  the  class  I  cytokine
receptor family, such as the receptors of interleukin-2 (IL-2), IL-3, IL-4, IL-6, IL-11, IL-12,
granulocyte colony-stimulating factor (G-CSF) or leukemia inhibitory factor (LIF).  OB-Rb
has  full  signaling capabilities  and is  able  to  activate  the  JAK/STAT pathway,  the  major
pathway used by leptin to exert  its  effects [Cirillo et  al  2008].  It  has receptors on many
other  cell  types  such as  adipocytes,  osteoclasts,  endothelial  cells,  lung and kidney cells,
mononuclear blood cells, muscle, endometrial and liver cells [Hegyi et al 2004].
5.5. Association between leptin and TNF-alpha and insulin resistance
Placental  leptin  mRNA  production  is  upregulated  by  tumour  necrosis  factor  (TNF)  α
and interleukin (IL)-6.  Most  studies have found increased leptin concentrations in GDM.
Moreover,  hyperleptinaemia  in  early  pregnancy  appears  to  be  predictive  of  an  in‐
creased  risk  to  develop  GDM  later  in  pregnancy  independent  of  maternal  adiposity
(Hotamistigil  et  al  1993,  Das  2002,  Kirwan  et  al  2002,).  The  human  placenta  expresses
virtually  all  known  cytokines  including  tumor  necrosis  factor  (TNF)-α,  resistin,  and
leptin,  which are also produced by the adipose cells  (Qasim etal  2008,  Rabe et  al.  2008).
The discovery that  some of  these adipokines as  key players  in the regulation of  insulin
action  suggests  possible  novel  interactions  between  the  placenta  and  adipose  tissue  in
understanding  pregnancy-induced  insulin  resistance,  which  is  evident  in  gestational
diabetes  mellitus (GDM) (Winzer et  al  2004).
5.6. Inflammatory mediators in diabetes mellitus
Gestational  diabetes  mellitus  is  characterized  by  an  amplification  of  the  low-grade
inflammation already existing in normal pregnancy (Retnakaran et al 2010). This hypothe‐
sis  is  supported  by  increased  circulating  concentrations  of  inflammatory  molecules  like
TNFα and IL-6 in GDM pregnancies.  TNFα is  one of  the candidate molecules responsi‐
ble  for  causing  insulin  resistance.  Comparison  of  the  placental  gene  expression  profile
between normal and diabetic pregnancies indicates that increased leptin synthesis in GDM
is associated with a higher production of proinflammatory cytokines, e.g. IL-6 and TNFα
causing a chronic inflammatory environment that enhances leptin production (Pickup et al
2000, Winkler et al 2002, Gao et al 2008). Thus, compared with normal pregnant women,
placental  leptin  expression  in  patients  with  GDM  is  increased.  Conversely,  leptin  itself
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increases production of TNFα and IL-6 by monocytes and stimulates the production of CC-
chemokine ligands. Elevated leptin concentrations in turn amplify inflammation
6. Link between inflammation and insulin resistance
In 1876 Ebstein asserted that sodium salicylate could make the symptoms of diabetes mellitus
totally disappear. Similarly, in 1901 Williamson found that “sodium salicylate had a definite
influence in greatly diminishing the sugar excretion”(Shoelson 2002, Shoelson et al 2006,
Cefalu 2009). Increased levels of markers and mediators of inflammation and acute-phase
reactants such as fibrinogen, C-reactive protein (CRP), IL-6, plasminogen activator inhibitor-1
(PAI-1), sialic acid, and white cell count correlate with incident T2D (Sternberg et al 1992, Bo
et al 2005, Kim et al. 2008). Markers of inflammation and coagulation are reduced with intensive
lifestyle intervention. This was confirmed in the diabetes prevention program (DPP Research
Group 2005). Experimental evidence have also confirmed that adipose tissue–derived proin‐
flammatory cytokines such as TNF-α could actually cause insulin resistance (Wolf et al 2003,
Dandona et al 2004, Hu et al 2004, Heitritter et al 2005). Hotamisligil and colleagues (1993,
1994 ) and Karasik and Colleagues (1993 ) first showed that the proinflammatory cytokine
TNF-α was able to induce insulin resistance. The concept of fat as a site for the production of
cytokines and other bioactive substances quickly extended beyond TNF-α to include leptin,
IL-6, resistin, monocyte chemoattractant protein-1 (MCP-1), PAI-1, angiotensinogen, visfatin,
retinol-binding protein-4, serum amyloid A (SAA), and others (Dandona et al 2004). Adipo‐
nectin is similarly produced by fat, but expression decreases with increased adiposity. While
leptin and adiponectin are true adipokines that appear to be produced exclusively by adipo‐
cytes, TNF-α, IL-6, MCP-1, visfatin, and PAI-1 are expressed as well at high levels in activated
macrophages and/or other cells(Baer et al 1998). Sites of resistin production are more complex;
they include macrophages in humans but both adipocytes and macrophages in rodents. TNF-
α, IL-6, resistin, and other pro- or antiinflammatory cytokines appear to participate in the
induction and maintenance of the subacute inflammatory state associated with obesity
(Thyfault et al 2005). MCP-1 and other chemokines have essential roles in the recruitment of
macrophages to adipose tissue. These cytokines and chemokines activate intracellular
pathways that promote the development of insulin resistance and T2D (Wu et al 2002, de
Victoria et al. 2009).
6.1. Mechanisms of insulin resistance by pro-inflammatory cytokines
The JNK (also referred to as SAPK) and p38 MAPKs are members of the complex superfamily
of MAP serine/threonine protein kinases. This superfamily also includes the ERKs (Lewis et
al 1998). In contrast to ERKs (also referred to as MAPKs), which are typically activated by
mitogens, JNK/SAPK and p38 MAPK are known as stress-activated kinases. This can be
attributed to the fact that the activities of these enzymes are stimulated by a variety of
exogenous and endogenous stress-inducing stimuli including hyperglycemia, ROS, oxidative
stress, osmotic stress, proinflammatory cytokines, heat shock, and UV irradiation (Tibbles et
al 1999). Many of the more typical proinflammatory stimuli simultaneously activate JNK and
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IKKβ pathways, including cytokines and TLRs (Seger and Krebs 1995). Concordantly, genetic
or chemical inhibition of either JNK or IKKβ/NF-κB can improve insulin resistance. The several
mechanisms have been postulated to explain how obesity activates JNK and NF-κB. These can
be separated into receptor (Lowes et al 2002) and nonreceptor pathways (Tamura et al 2002).
Proinflammatory cytokines such as TNF-α and IL-1β activate JNK and IKKβ/NF-κB through
classical receptor-mediated mechanisms that have been well characterized (Shen et al 2001,
Tournier et al 2001). JNK and IKKβ/NF-κB are also activated by pattern recognition receptors,
defined as surface proteins that recognize foreign substances. These include the Toll-like
receptors (TLRs) and the receptor for advanced glycation end products (RAGE). Many TLR
ligands are microbial products, including LPS and lipopeptides (Tamura et al 2002).
6.2. Transcription versus phosphorylation in the pathogenesis of insulin resistance
JNK is a stress kinase that normally phosphorylates the c-Jun component of the AP-1 tran‐
scription factor, but to date there are no known links between this well-established transcrip‐
tional pathway and JNK-induced insulin resistance. JNK has been shown to promote insulin
resistance through the phosphorylation of serine residues (Shen et al 2001, Tournier et al
2001). Insulin receptor signaling that normally occurs through a tyrosine kinase cascade is
inhibited by counterregulatory serine/threonine phosphorylations.
6.3. IKK β signaling pathway and insulin resistance
Unlike JNK, IKKβ does not phosphorylate IRS-1 to cause insulin resistance but causes insulin
resistance through transcriptional activation of NF-κB. Increased lipid deposition in adipo‐
cytes leads to the production of proinflammatory cytokines, including TNF-α, IL-6, IL-1β, and
resistin, which further activate JNK and NF-κB pathways through a feed-forward mechanism
(Hou et al 2008). In addition to the cytokines, there is upregulated expression of transcriptions
factors, receptors, and other relevant proteins including chemokines that recruit monocytes
and stimulate their differentiation into macrophages.
Cytokines and chemokines produced locally include MCP-1 and macrophage inflammatory
protein-1α (MIP-1α), MIP-1β, MIP-2, and MIP-3α. T cell activation leads to expression of IFN-
γ and lymphotoxin; macrophages, endothelial cells, and SMCs produce TNF-α; and together
these stimulate the local production of IL-6 in the atheroma
6.4. Oxidative stress and activation of JNK and NF-κB pathways
In addition to proinflammatory cytokine and pattern recognition receptors, cellular stresses
activate JNK and NF-κB, including ROS and ER stress. Elevated glucose cause oxidative stress
through (1) increased production of mitochondrial reactive oxygen species (ROS), (2) Non-
enzymatic glycation of proteins, (3) Glucose autoxidation (Elevated free fatty acids (FFA) and
beta oxidation (Tibbles et al 1999, Evans et al 2002, Lewis et al 2002. Muoio et al. 2008). Systemic
markers of oxidative stress increase with adiposity, consistent with a role for ROS in the
development of obesity-induced insulin resistance, (Ozdemir et al 2005). One potential
mechanism is through the activation of NADPH oxidase by lipid accumulation in the adipo‐
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cyte, which increases ROS production. This mechanism was shown to increase the production
of TNF-α, IL-6, and MCP-1, and decrease the production of adiponectin (Barbour et al 2007).
Consistent with this, the antioxidant N-acetyl cysteine can reduce ROS and improve insulin
resistance in a hyperglycemia-induced model (Pieper et al 1997, Ozkilic et al 2006). Lipid
accumulation also activates the unfolded protein response to increase ER stress in fat and liver.
ER stress has been shown to activate JNK and subsequently, lead to serine phosphorylation of
insulin receptor substrate-1 (IRS-1), but as with all of the stimuli, ER stress similarly activates
NF-κβ (Evans et al 2002)
7. Health implications of cytokines, lipid metabolism, inflammation and
GDM
The  triad  of  cytokines,  lipid  metabolism  and  inflammation  are  hooked  together  by  a
biological  thread  of  oxidative  stress  and  pathogenetic  end-point  of  insulin  resistance.
Oxidative stress inhibits expression of Pax 3, a gene that is essential for neural tube closure,
and possibly congenital cardiac anomalies which have been associated with uncontrolla‐
ble diabetes in pregnancy before and in early pregnancy (Chang et al 2003). The associa‐
tion between GDM and macrosomia is real, with a secondary effect of increased cesarean
section and increased risk of postpartum genital infection and development of overt type
2  diabetes  mellitus.  The  markers  of  inflammation,  dyslipidemia,  oxidative  stress  and
endothelial  dysfunction  may  provide  additional  information  about  a  patient's  risk  of
developing  cardiovascular  disease  and  hypertension.  This  may  provide  new  attractive
targets for drug development.
8. Intervention strategies
GDM offers an important opportunity for the development for testing and the implementation
of clinical strategies in diabetic prevention (Volpe et al 2007). The main objective should be to
improve insulin sensitivity and prevent diabetes mellitus.
8.1. Lifestyle modification
Lifestyle modifications have been shown to be successful in decreasing the progression to
T2DM in several populations, including American, Finnish and Asian, so it seems rational to
consider similar interventions in women with a history of GDM (An Empowered Based
Diabetic Prevention 2011). The ACOG (2003), RCOG Guidelines (2011), NICE Guidelines
(2009) and the ADA (2005) all recommend that women at increased risk for T2DM should be
counseled about the benefits of diet, exercise, and weight reduction and/or maintenance in an
effort to prevent the development of T2DM as part of preconception care.
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8.2. Breast-feeding
Breast-feeding is associated with reduced blood glucose levels and a reduced incidence of
T2DM among both women with a history of GDM and women in the general population.
Lactation has also been associated with postpartum weight loss, reduced long-term obesity
risk, and a lower prevalence of the metabolic syndrome (O’Reilly et al 2003).
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Figure 1. Mechanisms of Insulin Resistance and Gestational diabetes Fatty acid metabolites (long-chain acyl-CoA
[LCCoA] and diacylglycerol [DAG]) trigger a serine/threonine kinase cascade andl protein kinase C, to induce serine/
threonine phosphorylation. This inhibits IRS-1 binding and activation of PI 3-kinase and insulin signalling with resul‐
tant reduced insulin-stimulated glucose transport. Obesity-associated changes in secretion of adipokines and inflam‐
matory IKKβ and NF-kβ and JNK pathways through ligands for TNF-α, IL-1, Toll and AGE receptors, intracellular stresses
like Reactive oxygen species,Ceramide and PKC isoforms. These factors modulate insulin signalling, through activation
of NF-kβ and cause insulin Resistance( Shoelson et al 2006, Qatanani et al 2007, Savage et al 2007,)
8.3. Pharmacologic interventions
Insulin is the drug to use, especially in GDM. Drugs with anti-inflammatory and vascular
effects have future potential of being used in interventions aimed at reducing the enormous
cardiovascular burden associated with Type 2 diabetes (Ziegler 2005). Use of sodium salicylate
(Aspirin) (Hostamistigil et al 1993, Karasik et al 1993) has the concerns with high dose and
possible side-effect of peptic ulceration. The use of antioxidant E and C reduces embryopathy
in animal model (Cederberg ) and in human with use of N-acetyl Cysteine has beneficial effects
(Ozkilic et al 2006).
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9. Concluding remarks
Recent advances in the understanding of carbohydrate metabolism during pregnancy, suggest
that preventive measures should be aimed at improving insulin sensitivity in women with
strong risk factors of developing GDM. The mechanisms involved in the pathogenesis of
insulin resistance and Gestational Diabetes Mellitus are summarized in Figure 1. Further
research is needed to elucidate the mechanisms and consequences of alterations in lipid
metabolism during pregnancy (Marseille-Tremblay et al 2008). Inflammation-induced insulin
resistance is certainly increasing in parallel with the epidemic of obesity. Strategies for
reducing this trend should be part of the Public Health initiatives.
9.1. Future directions
There is need for genetic studies especially from the Human Genome to identify those with
candidate genes for diabetes and epigenetic factors that may affect gene expression and
predisposition to inflammation. It should be possible to directly target inflammation with
pharmacological interventions to treat and/or prevent insulin resistance and T2D and modu‐
late risk for CVD and other metabolic conditions. In addition to anti-inflammatory drugs such
as NF-κβ inhibitors and IL-1 receptor antagonists already known to improve inflammatory
and glycemic parameters, should have utility to block the prolonged exposure to inflammatory
danger signals may further enhance the metabolic and cardiovascular outcome of obese
patients. Early recognition and management of women predisposed to develop T2DM is
crucial in the development of primary health care strategies, modification of lifestyle, and
dietary habits significantly to prevent or delay of insulin resistance and development of
glucose intolerance.
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